Immuneering (NASDAQ:IMRX) Cut to “Sell” at Wall Street Zen

Wall Street Zen lowered shares of Immuneering (NASDAQ:IMRX) from a hold rating to a sell rating in a research note published on Saturday morning.

IMRX has been the topic of a number of other research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Immuneering in a research report on Monday, December 15th. Mizuho set a $12.00 price objective on shares of Immuneering in a research note on Wednesday, October 29th. Needham & Company LLC upped their price objective on shares of Immuneering from $8.00 to $11.00 and gave the company a “buy” rating in a report on Monday, September 15th. HC Wainwright reissued a “buy” rating and set a $11.00 target price on shares of Immuneering in a report on Tuesday, September 30th. Finally, Leerink Partnrs raised Immuneering to a “strong-buy” rating in a report on Friday, October 31st. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $16.50.

Immuneering Price Performance

NASDAQ IMRX opened at $5.91 on Friday. The company has a market cap of $381.61 million, a price-to-earnings ratio of -3.32 and a beta of 0.46. The stock’s fifty day moving average price is $6.44 and its 200 day moving average price is $5.37. Immuneering has a 1 year low of $1.10 and a 1 year high of $10.08.

Immuneering (NASDAQ:IMRX) last issued its quarterly earnings results on Wednesday, November 12th. The company reported ($0.38) EPS for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.01). Research analysts expect that Immuneering will post -1.86 earnings per share for the current year.

Insider Transactions at Immuneering

In related news, Director Peter Feinberg acquired 7,500 shares of the firm’s stock in a transaction on Friday, October 3rd. The shares were acquired at an average cost of $6.67 per share, with a total value of $50,025.00. Following the completion of the acquisition, the director directly owned 156,766 shares in the company, valued at approximately $1,045,629.22. This trade represents a 5.02% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders have acquired 20,800 shares of company stock worth $143,754 over the last quarter. Company insiders own 22.90% of the company’s stock.

Hedge Funds Weigh In On Immuneering

A number of hedge funds have recently made changes to their positions in IMRX. Flower City Capital acquired a new stake in shares of Immuneering in the second quarter valued at about $108,000. Kingsview Wealth Management LLC purchased a new stake in shares of Immuneering during the 2nd quarter valued at approximately $47,000. HighTower Advisors LLC raised its position in shares of Immuneering by 17.7% during the 1st quarter. HighTower Advisors LLC now owns 83,960 shares of the company’s stock valued at $128,000 after buying an additional 12,600 shares during the period. Palumbo Wealth Management LLC acquired a new position in Immuneering in the third quarter valued at approximately $343,000. Finally, China Universal Asset Management Co. Ltd. purchased a new position in Immuneering in the third quarter worth approximately $35,000. Institutional investors and hedge funds own 67.65% of the company’s stock.

About Immuneering

Immuneering (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering’s machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company’s AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company’s lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.